Aplisol (Tuberculin Purified Protein Derivative, Diluted)
Aplisol is a sterile aqueous solution of tuberculin purified protein derivative (PPD), indicated as an aid in the detection of infection with Mycobacterium tuberculosis. It is administered intradermally via the standard Mantoux test and is available as a stabilized, ready-to-use solution that requires no further dilution prior to administration.
Key Benefits:
- Indicated as a diagnostic aid for the detection of Mycobacterium tuberculosis infection using the standard intradermal Mantoux test
- Clinically bioequivalent in potency to the standard PPD-S (5 TU per 0.1 mL) of the U.S. Public Health Service, National Centers for Disease Control
- Ready for immediate use without further dilution, supplied as a stabilized solution
- Tuberculin skin testing is not contraindicated for persons vaccinated with BCG; results may be used to support or exclude diagnosis of M. tuberculosis infection
- Labeled as latex free; available in 1 mL (10 tests) and 5 mL (50 tests) multiple dose vials
Dosage & Administration:
The standard dose is 0.1 mL of Aplisol administered intradermally on the volar aspect of the forearm using the Mantoux technique, equivalent to 5 tuberculin units (TU). A separate, sterile, single-use disposable syringe and needle must be used for each patient. Test results are read 48 to 72 hours after injection by measuring the diameter of induration in millimeters; erythema has no diagnostic value. Positive reaction thresholds (≥5 mm, ≥10 mm, or ≥15 mm) are interpreted based on patient risk factors per current guidelines.
Why Choose Aplisol?:
Aplisol is a ready-to-use, stabilized tuberculin PPD solution that is clinically bioequivalent to the U.S. Public Health Service standard PPD-S, formulated specifically for intradermal Mantoux testing as an aid in the diagnosis of tuberculosis.
Warnings:
- Aplisol is contraindicated in patients who previously experienced severe reactions (vesiculation, ulceration, or necrosis) at the test site; such reactions may recur and can result in scarring
- Systemic allergic reactions including anaphylaxis/anaphylactoid reactions have been reported; epinephrine should be immediately available during administration
- False-negative results may occur in immunocompromised individuals, including those with HIV infection, patients on corticosteroids or immunosuppressive agents, or those with conditions affecting cell-mediated immunity; a negative test should not be used to exclude active tuberculosis in patients with compatible symptoms
Disclaimer: This product description was generated by AI and is intended for informational purposes only. Please consult the latest package insert.
